Here, we investigated this strategy in the poorly-immunogenic 4T1 murine tumor model of metastatic triple negative breast cancer (TNBC), combining a murine OX40L fusion protein agonist (OX40L-FP) with a poxvirus-based cancer vaccine (MVA-Twist-TRICOM). Here, TNFSF4 is linked to triple-negative breast carcinoma.